Pando Bioscience Analysis: $500K Raised
What is Pando Bioscience?
Pando Bioscience develops generative AI designed enzymes for pharmaceutical manufacturing, diagnostics, and molecular biology applications. Its protein specific models combine public and proprietary data with a high throughput screening platform, and the company claims a design build test learn cycle under one month. The company says its internally trained models achieve hit rates two orders of magnitude higher than models trained only on public databases.
Location
134 Coolidge Avenue Suite 2, Watertown, Massachusetts 02472, United States
Employees
1-10
Founded
2022
Product Features & Capabilities
- proprietary engineered enzymes for molecular biology applications, tailored enzyme solutions for cost reduction, efficiency improvement, and profitability enhancement, ultra-high-throughput screening platform for enzyme optimization
How much Pando Bioscience raised
1: - $500,000
April 5, 2023Lead Investor: Creative Destruction Lab, Y Combinator, Endless Frontier Labs, Other People's Capital
Who are the founders of Pando Bioscience
Market Focus
Pando Bioscience primarily focuses on the pharmaceutical manufacturing and diagnostics industry, utilizing AI-driven synthetic biology for enzyme engineering.
Investors
- Creative Destruction Lab
- Y Combinator
- Endless Frontier Labs
- Other People's Capital
Competitors Overview
Pando Bioscience operates in the synthetic biology and enzyme engineering market, where it faces competition from several notable companies:
-
Ginkgo Bioworks: Specializes in custom organism design and has a strong focus on using synthetic biology for various applications, including pharmaceuticals. Their advantage lies in their extensive platform for organism engineering and partnerships across multiple industries.
-
Codexis: Focuses on enzyme optimization and engineering, similar to Pando. Codexis has a well-established reputation in the pharmaceutical sector, leveraging its proprietary technology for enzyme development, which may provide them with a competitive edge in specific applications.
-
Novozymes: A leader in enzyme production, Novozymes has a broad portfolio of products for various industries, including pharmaceuticals. Their extensive experience and established market presence give them a significant advantage in terms of scale and distribution.
-
Illumina: While primarily known for genomic sequencing, Illumina's technologies are integral to synthetic biology research and development. Their advanced sequencing capabilities can enhance enzyme engineering processes, making them a relevant competitor.
-
Eurofins Scientific: Offers a wide range of testing services, including those related to synthetic biology. Their comprehensive service offerings can be advantageous for companies looking for integrated solutions in enzyme development and testing.
-
Mammoth Biosciences: Focuses on CRISPR-based diagnostics and gene editing, which intersects with enzyme engineering. Their innovative approach to diagnostics may provide unique advantages in the pharmaceutical sector.
These competitors differ in their specific focus areas, technological capabilities, and market strategies, which can influence their competitive positioning relative to Pando Bioscience.
See something that needs updating? Suggest edits to this profile.